Autoimmune Disease Clinical Trial
Official title:
A Randomized, Double-blinded, Dose-escalation Phase Ia Study to Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers
The goal of clinical trial is to evaluate the safety and tolerability of SCT650C in healthy participants.
Interleukin-17A (IL-17A) is a new potential therapeutic target which plays important role in pathogenesis of several autoimmune disorders including psoriasis, rheumatoid arthritis, possibly - systemic lupus erythematosus (SLE) and multiple sclerosis (MS). SCT650C is a novel humanized monoclonal antibody against human IL-17A developed by Sinocelltech which is now on the first step of clinical evaluation. SCT650C-612-1-01 study is the first-in-human clinical trial which is intended to evaluate tolerability, safety, pharmacokinetics and immunogenicity of SCT650C in healthy volunteers. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT01934764 -
Identification of Correlations Between Reaction to Biotine and Autoimmune Diseases
|
N/A | |
| Recruiting |
NCT01665196 -
18F-FDG PET/CT for IgG4-Related Disease
|
Early Phase 1 | |
| Withdrawn |
NCT02948855 -
Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
|
||
| Completed |
NCT01815996 -
Identify Clinical Conditions That Increase Circulating DNA Levels
|
||
| Completed |
NCT02434458 -
Sudoscan in Patients With Autoimmune Disorders
|
N/A | |
| Completed |
NCT02263703 -
Immunogenicity of HPV Vaccine in Immunosuppressed Children
|
Phase 3 | |
| Completed |
NCT00013689 -
Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome
|
Phase 1 | |
| Completed |
NCT00340600 -
Continuation of Follow-up of DES-Exposed Cohorts
|
||
| Completed |
NCT02647866 -
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
|
Phase 2 | |
| Active, not recruiting |
NCT00716066 -
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
|
Phase 2 | |
| Completed |
NCT00351377 -
Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
|
Phase 3 | |
| Completed |
NCT00114530 -
Scleroderma: Cyclophosphamide or Transplantation
|
Phase 2/Phase 3 | |
| Completed |
NCT00001630 -
Treatment of Autoimmune Thrombocytopenia (AITP)
|
Phase 1 | |
| Completed |
NCT00372177 -
The Use of Anti-CD4 Monoclonal Antibody (mAb)-Fragment for the Imaging of Chronic Inflammation in Patients With Active Rheumatoid Arthritis
|
Phase 1/Phase 2 | |
| Completed |
NCT00065390 -
Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
|
Phase 1 | |
| Completed |
NCT00001658 -
Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections
|
Phase 4 | |
| Recruiting |
NCT03816345 -
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
|
Phase 1 | |
| Completed |
NCT00001306 -
Steroid Therapy in Autoimmune Premature Ovarian Failure
|
N/A | |
| Recruiting |
NCT03715699 -
Leflunomide Treatment for IgG4-RD
|
N/A | |
| Completed |
NCT02925351 -
Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
|
Early Phase 1 |